Prokinetics influence the pharmacokinetics of rabeprazole

Digestion

Volumn 78, Issue 2-3, 2008, Pages 67-71

  Arai, Katsuhito ^a   Takeuchi, Yoshiaki ^a   Watanabe, Hideki ^a   Tsukurimichi, Atsushi ^a   Uchida, Naoki ^a   Imawari, Michio ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

Mosapride citrate; Pharmacokinetics; Rabeprazole sodium

Indexed keywords

MOSAPRIDE CITRATE; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AREA UNDER CURVE; BENZAMIDES; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MORPHOLINES;

EID: 54249135372     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000165351     Document Type: Article

References (23)

1. Furuta T, Shirai N, Sugimoto M, Nakamura A, Okudaira K, Kajimura M, Hishida A: Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status. Aliment Pharmacol Ther 2005;22:67-74.
2. Londong W, Londong V, Cederberg C, Steffen H: Dose-response study of omeprazole on meal-stimulated gastric acid secretion and gastrin release. Gastroenterology 1983;85:1373-1378.
3. Hatlebakk JG, Katz PO, Kuo B, Castell DO: Nocturnal gastric acidity and breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998;12:1235-1240.
4. + ATPase. Annu Rev Pharmacol Toxicol 1995;35:277-305.
5. 4 selective agonist, beneficially affects pharmacokinetics of proton pump inhibitor. Gastroenterology 2005;128:A531.
6. Anderson T: Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Clin Pharmacokinet 1996;31:9-28.
7. Eisai Inc: Aciphex® (rabeprazole sodium) delayed-release tablets [online]. Available from URL: http://www.aciphex.com/pdf/aciphexpi.pdf.
8. 4 receptors. FASEB J 1996;10:1398-1407.
9. Talley NJ: Serotoninergic neuroenteric modulators. Lancet 2001;358:2061-2068.
10. Kanazumi T, Nakano H, Matsui Y, Ishikawa H, Shimizu R, Park S, Kuriya N: Prokinetic effect of AS-4370 on gastric emptying in healthy adult. Eur J Clin Pharm 1991;41:335-337.
11. Endo J, Nomura M, Morishita S, Uemura N, Inoue S, Kishi S, Kawaguchi R, Iga A, Nakaya Y: Influence of mosapride citrate on gastric motility and autonomic nervous function. J Gastroenterol 2002;37:888-895.
12. Itoh H, Nagago T, Takeyama M: Effect of mosapride citrate on human plasma levels of motilin, gastrin, somatostatin, and secretin. Biol Pharm Bull 2001;24:1072-1075.
13. Ishizaki T, Horai Y: Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment Pharmacol Ther 1999;13:27-36.
14. Kita T, Sakaeda T, Baba T, Aoyama N, Kakumoto M, Kurimoto Y, Kawahara Y, Okamura N, Kirita S, Kasuga M, Okumura K: Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors. Biol Pharm Bull 2003;26:386-390.
15. Horai Y, Kimura M, Furuie H, Matsuguma K, Irie S, Koga Y, Nagahama T, Murakami M, Matsui T, Yao T, Urae A, Ishizaki T: Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype. Aliment Pharmacol Ther 2001;15:793-803.
16. Sugimoto M, Furuta T, Shirai N, Kajimura M, Hishida A, Sakurai M, Ohashi K, Ishizaki T: Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to P450 2C19 genotype status. Clin Pharmacol Ther 2004;76:290-301.
17. Fukushima-Uesaka H, Saito Y, Watanabe H, et al: Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in Japanese population. Hum Mutations 2004;23:100.
18. Shimizu M, Uno T, Yasui-Furukori N, Sugawara K, Tateishi T: Effect of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. Eur J Clin Pharmacol 2006;62:597-603.
19. Yacyshyn BR, Thomson ABR: The clinical importance of proton pump inhibitor pharmacokinetics. Digestion 2002;66:67-78.
20. Madan K, Ahuja V, Kashyap PC, Sharma P: Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. Dis Esophagus 2004;17:274-278.
21. Miyamoto M, Haruma K, Takeuchi K, Kuwabara M: Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of prokinetics to proton pump inhibitor therapy. J Gastroenterol Hepatol 2007;23:746-751.
22. Carlsson L, Amos GJ, Andersson B, Drews L, Duker G, Wadstedt G: Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential? J Pharmacol Exp Ther 1997;282:220-227.
23. Hiyama T, Yoshihara M, Matuo K, Kusunoki H, Kamada T, Ito M, Tanaka S, Chayama K, Haruma K: Treatment of functional dyspepsia with serotonin agonist: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2007;22:1566-1570.